|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 13th Street NW |
Address2 | 11th Floor North |
City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400693064-140
|
||||||||
|
6. House ID# 415240013
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Melanie Nathanson |
Date | 1/13/2017 5:14:48 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 3504 - Creating High Quality Results and Outcome Necessary to Improve Chronic Care Act of 2016 - Issues related to palliative care, telemedicine and other issues related to better serving Medicare beneficiaries.
PL - 114- 255 - 21st Century Cures Act. Provisions to include help fight against opioid abuse.
H.R. 5327 - Continuing Appropriations and Military Construction, VA and Related Agencies Appropriations Act of 2017 and Zika Response and Preparedness Act. Issues regarding the funding of opioid related programs.
S. 524 - the Comprehensive Addition and Recovery Act- issues related to ensuring best prescribing practices for opioids in the country and solutions developed by BCBSMA to combat abuse.
H.R. 5447 - the Small Business Health Care Relief Act - issues regarding allowing small business owners the option to allow employees to purchase insurance in the individual market and the impact policies would have on state based marketplaces (SBMs)
Work on alternative payment models developed by BCBSMA and how they can apply nationally.
Issues related to advancing policies to improve end of life care for seriously ill individuals.
Issues related to delivery system reform.
Issues related to state-based marketplaces.
Issues related to Medicare coverage.
Issues related to post-enrollment support for newly insured.
Issues related to delivery system reform and innovation within the Medicare program.
Regulations on civil rights and non discrimination based on section 1557 of the ACA.
Issues related to ACA waivers - section 1332 of the law.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melanie |
Nathanson |
|
|
|
Megan |
Hauck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S. 3504 - Creating High Quality Results and Outcome Necessary to Improve Chronic Care Act of 2016 - Issues related to palliative care, telemedicine and other issues related to better serving Medicare beneficiaries.
PL - 114- 255 - 21st Century Cures Act. Provisions to include help fight against opioid abuse.
H.R. 5327 - Continuing Appropriations and Military Construction, VA and Related Agencies Appropriations Act of 2017 and Zika Response and Preparedness Act. Issues regarding the funding of opioid related programs for Medicare and Medicaid beneficiaries.
Work on alternative payment models developed by BCBSMA and how they can apply nationally.
Issues related to advancing policies to improve end of life care for seriously ill individuals.
Issues related to delivery system reform in Medicare and the private insurance market.
Issues related to delivery system reform and innovation within the Medicare program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Megan |
Hauck |
|
|
|
Melanie |
Nathanson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
PL - 114- 255 - 21st Century Cures Act. Provisions to include help fight against opioid abuse.
H.R. 5327 - Continuing Appropriations and Military Construction, VA and Related Agencies Appropriations Act of 2017 and Zika Response and Preparedness Act. Issues regarding the funding of opioid related programs.
S. 524 - the Comprehensive Addition and Recovery Act- issues related to ensuring best prescribing practices for opioids in the country and solutions developed by BCBSMA to combat abuse.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melanie |
Nathanson |
|
|
|
Megan |
Hauck |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |